Previous 10 | Next 10 |
NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross pro...
Gainers: Cumberland Pharmaceuticals CPIX +113%. GBS GBS +28%. NuZee (NASDAQ:NUZE) +25%. ImmunoGen IMGN +24%. MEI Pharma MEIP +23%. Vir Biotechnology VIR +16%. Seres Therapeutics (NASDAQ:MCRB) +16%. Molecular MOLN +15%. Clene (NASDAQ:CLNN) +15%. ImmunityBio IBRX...
If you’re looking for the best penny stocks to buy today, chances are you’re looking for trends. There are few ways to make money in the stock market as quickly as trading cheap stocks. In this case, momentum and catalysts are essential. These market events can help you determ...
The FDA has informed Avenue Therapeutics (NASDAQ:ATXI) that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee is tentatively scheduled for February 15, 2022. Shares up 3.6% premarket at $1.15. ...
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the FDA has informed the ...
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwr...
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics Avenue Therapeutics is a specialty pharmaceutical company whose mission is to...
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the closing of its public offering of 1,946,787 share...
Moving iMage Technologies MITQ +30% on FQ1 earnings. RLX Technology (NYSE:RLX) +19%. Xponential Fitness XPOF +18% on Q3 earnings. Farfetch FTCH +14% in talks to expand existing Luxury New Retail strategic partnership with Richemont Everspin Technologies MRAM +13% ...
AerSale (NASDAQ:ASLE) -36% on Q3 earnings release. Purple Innovation (NASDAQ:PRPL) -32% on Q3 earnings release. Poshmark (NASDAQ:POSH) -30% on Q3 earnings release. Upstart Holdings (NASDAQ:UPST) -23% on Q3 earnings release. AnPac Bio-Medical S...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...